secukinumab (Cosentyx)

following a full submission:

secukinumab (Cosentyx®) is accepted for restricted use within NHSScotland.

Indication under review: for the treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.

SMC restriction: for use in adult patients with active moderate to severe HS for whom adalimumab is contraindicated or otherwise unsuitable, including those who have failed to respond or have lost response to prior adalimumab treatment.

In two phase III studies in patients with moderate to severe HS, the proportion of patients who achieved a clinical response (defined as at least a 50% decrease in abscess and inflammatory nodule [AN] count with no increase in the number of abscesses and/or in the number of draining fistulae) was significantly increased with secukinumab (every two weeks) compared with placebo.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.